About
As the likelihood increases that PCPs will become more involved in the management of testosterone therapy, it is important for them to understand how to evaluate and treat patients according to clinical guidelines and in the context of each patient’s individual goals, needs, preferences, histories, comorbidities, and risk factors.4,13,15 Furthermore, individual patients presenting to primary care may have unique concerns that necessitate a tailored approach to initiating, titrating, and monitoring testosterone therapy, and the provision of follow-up care.15 Clinical practice guidelines have been published by various societies and associations in different global regions, such as the Endocrine Society, European Academy of Urology, and European Association of Urology (EAU) in Europe; International Society of Sexual Medicine (ISSM); and American Urological Association (AUA), American College of Physicians (ACP), and Canadian Urological Association (CUA) guidelines in North America. The range of treatment options and the diversity of patients’ goals, preferences, comorbidities, and risk factors necessitate an individualized approach to testosterone therapy that considers each patient’s clinical needs alongside the distinct features of different testosterone formulations. Preventive Services Task Force recommends against routine PSA screening and does not specify its recommendation on digital rectal examination.61 Therefore, physicians and patients should engage in shared decision making, weighing the risks and benefits of ongoing prostate cancer screening in the context of testosterone therapy. In the meantime, physicians must counsel patients that the cardiovascular risks and benefits of testosterone therapy are uncertain and should engage in shared decision making.9,11,38 There is some evidence supporting the use of testosterone therapy as second-line therapy in men with low testosterone when phosphodiesterase-5 inhibitors are ineffective.18,19 There is no evidence that testosterone improves erectile function in men with normal testosterone levels. Patients receiving testosterone therapy should be monitored to ensure testosterone levels rise appropriately, clinical improvement occurs, and no complications develop.Over a mean duration of 27.5 months, 1,223 men received testosterone therapy, and 7,486 were placed on placebo. Vigen et al. (2013)363 conducted a retrospective analysis of patients who received a prescription for testosterone therapy after coronary angiography. Two of the trials and one meta-analysis pointed to an increased risk of cardiovascular events,363, 364, 366 two revealed no cardiovascular risk,233, 367 and one was neutral with respect to risk.373 The Corona meta-analysis,372 which showed that there was no increased risk of cardiovascular events, was not officially reviewed but was taken into consideration in the final analysis.
Primary hypogonadism is the failure of the testes to produce sufficient testosterone, whereas secondary hypogonadism is caused by decreased production of luteinizing hormone.3 Hypogonadism may also be classified by timing of onset (i.e., pre- or postpubertal). Decreased production of testosterone by testes in men is categorized as hypogonadism, which is classified as primary, secondary, or mixed. Testosterone therapy is increasingly common in the United States, and many of these prescriptions are written by primary care physicians.
Removal of the system results in a rapid drop in testosterone levels.433 In the case of topical patches, the testosterone levels achieved directly relate to the amount of surface area exposed to drug.430 Topical gels and liquids generally demonstrate less variability in absorption uptake when compared to other therapies.417 After application, steady state levels are achieved within hours, with testosterone levels returning to baseline within 4 days of discontinuation.418, 419 The current guideline only included studies in the meta-analysis that used morning total testosterone 411 Meta-analyses of RCTs and cohort studies provide the highest levels of evidence and reliability, followed by individual RCTs, prospective cohorts, retrospective cohorts, and observational studies. Thousands of articles on testosterone deficiency and testosterone therapy have been published over the past several decades.
As you grow older, the level of testosterone in your body naturally decreases, leading to a variety of changes. Testosterone levels are at their highest during adolescence and early adulthood. These guidelines are provided only as assistance for physicians making clinical decisions regarding the care of their patients. There is not enough evidence to determine if this is the best treatment for all transgender individuals or only for those submitted to oophorectomy. Gonadotrophin levels can be suppressed, but in some cases, they can be above normal follicular phase ranges, suggesting that the hypothalamus-hypophysis-ovary (HHO) axis may not be suppressed by male physiologic levels of androgen.1 This reinforces the importance of contraceptive measures for transgender men that practice penis-in-vagina intercourse with men or transgender women. Typically, testosterone can induce alteration in the vaginal epithelium, clinically manifested by signs of mucosa atrophy.
Three others did stop testosterone in response to the PSA bounce, two of whom had negative prostate biopsies. Testosterone therapy can be considered in those men who have undergone radical prostatectomy (RP) with favorable pathology (e.g., negative margins, negative seminal vesicles, negative lymph nodes), and who have undetectable PSA postoperatively. If the testosterone concentration is increased further, rather than further proliferation, the cells reduce their rate of proliferation.343, 344 This phenomenon is known as the bipolar testosterone concept. In-vitro experiments have shown that prostate cancer cells fail to proliferate in the absence of testosterone; once testosterone is introduced, an initial proliferative response is observed followed by a plateau after a certain testosterone concentration is reached. The other men in the study already had metastatic disease at the time of testosterone initiation. However, an analysis of Huggins' original paper reveals that this assumption was based on a single patient who was cancer and androgen therapy naïve at study onset. Increasing patient age and increasing duration of prior exogenous testosterone use both significantly reduced the likelihood of reaching the 5 million TMSC benchmark.
Other population-based studies have attempted to measure prevalence, but have not used standard methodology, which makes arriving at a definitive number of testosterone deficiency difficult. A review by Millar et al.4 searched MEDLINE and Embase databases from January 1966 to July 2014 for studies that compared clinical indication of low testosterone along with a measurement of serum testosterone in men. Considering the inherent confusion surrounding testosterone therapy in the current prescribing landscape, the AUA believes it is imperative to be as explicit as possible and present the reader the most complete information, which will optimize the efficacy and safety of testosterone therapy. A Clinical Principle is a statement about a component of clinical care that is widely agreed upon by urologists or other clinicians for which there may or may not be evidence in the medical literature.
Men who have a history of chronic corticosteroid use have been shown to be at risk for low testosterone levels. BMD increased in patients treated with testosterone therapy leading the authors to conclude that younger testosterone deficient men may benefit from having routine DEXA scans performed, particularly those with concomitant low E2 and low BMI.89 It is believed that as many as one-third of older men have unexplained anemia,77 and data from observational studies indicate that there is a significant association between low testosterone levels and reduced hemoglobin (Hb) levels. The European Male Aging Study (EMAS)8 studied 3,369 men (mean age 59 years) and culled data on their sexual, physical, and psychological symptoms along with morning total testosterone measurements. Point estimates that measure the difference in testosterone levels between men with and without ED may appear statistically significant, but these estimates are not always clinically meaningful. Despite the methodological limitations, individual studies have shown a link between low testosterone levels and ED. Among men with traditional (10p.m. to 6a.m.) sleep patterns, peak testosterone values occur around 3-8a.m., with 32-39% of the diurnal total decline occurring within the first 30 minutes of waking.18-23 Older men experience diurnal blunting and more stability in testosterone levels throughout the day, while younger men undergo greater variation.